Regeneron Pharmaceuticals

Yahoo Finance • yesterday

Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results

Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped. Continue Reading... Full story

Yahoo Finance • 2 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such investors are advised to contact Danielle Peyt... Full story

Yahoo Finance • 7 days ago

Lam Research Takes Over #59 Spot From Regeneron Pharmaceuticals

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Lam Research Corp (Symbol: LRCX) has taken over the #59 spot from Regeneron Pharmaceuticals, Inc. (Symbol: REGN), according to ETF... Full story

Yahoo Finance • 7 days ago

Jim Cramer on Regeneron: “There Could Be Some More Downgrades”

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was among the stocks Jim Cramer discussed while explaining how investors can navigate the current market rotation. Cramer highlighted the company’s unsuccessful trial, as he remarked: Finally,... Full story

Yahoo Finance • 8 days ago

Why Regeneron (REGN) Shares Are Trading Lower Today

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 10.5% in the afternoon session after its experimental cancer treatment failed to meet the main goal in a late-stage study for patients with a type of advanced skin canc... Full story

Yahoo Finance • 10 days ago

US stocks end mixed as tech stocks slide, Treasury yields climb

STORY: Wall Street's main indexes ended mixed on Monday, with the Dow adding about a third of a percent, the S&P 500 little changed and the tech-heavy Nasdaq shedding half a percent.Ongoing worries about the disruption of oil supplies, inf... Full story

Yahoo Finance • 10 days ago

US Equity Indexes Off Session Lows as Trump Postpones Iran Attack

US equity indexes closed mixed, albeit off session lows, as President Donald Trump agreed to delay a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 10 days ago

US Equity Markets Mixed as Investors Weigh Reports of Iran's Updated Peace Proposal

US equity indexes were mixed on Monday as investors weighed reports of an updated peace proposal fro PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 10 days ago

Stocks Pressured by a Rebound in Crude Prices and Bond Yields

The S&P 500 Index ($SPX) (SPY) today is down -0.20%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.57%.  June E-mini S&P futures (ESM26) are down -0.28%, and June E-mini Na... Full story

Yahoo Finance • 10 days ago

Noteworthy Monday Option Activity: NEE, WYNN, REGN

Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in NextEra Energy Inc (Symbol: NEE), where a total volume of 41,783 contracts has been traded thus far today, a contract volume w... Full story

Yahoo Finance • 10 days ago

Stocks Mixed as Crude Oil Prices and Bond Yields Fall

The S&P 500 Index ($SPX) (SPY) today is up +0.07%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.29%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.25%.  June E-mini S&P futures (ESM26) are up +0.10%, and June E-mini Nasdaq f... Full story

Yahoo Finance • 10 days ago

Stocks making the biggest moves midday: Regeneron, Dominion, Mobileye, Viking and more

Check out the companies making the biggest moves in midday trading: Dominion Energy — Shares popped more than 9% after NextEra Energy announced a deal to acquire the company in an all-stock transaction. NextEra said the combination of the... Full story

Yahoo Finance • 10 days ago

The Surprising Reason Regeneron Pharmaceuticals Just Dropped 12%

Regeneron Pharmaceuticals stock crashed Monday after its experimental melanoma treatment failed in Phase 3 testing. Continue Reading... Full story

Yahoo Finance • 10 days ago

Sector Update: Healthcare Stocks Decline Pre-Bell Monday

Healthcare stocks were declining pre-bell Monday, with the State Street Health Care Select Sector SP PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 10 days ago

New Drone Incidents in Middle East Keep Tensions High, Nudge US Equity Futures Pre-Bell Lower

US equity futures were lower pre-bell Monday as tensions remain high in the Middle East after the UA PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 10 days ago

Stocks making the biggest moves premarket: Regeneron, Dominion Energy, Macy's & more

Check out the companies making the biggest moves premarket: Regeneron Pharmaceuticals — The drugmaker fell more than 11% after its treatment for a skin cancer missed goals in a late-stage trial. Macy's — The department store shares jumped... Full story

Yahoo Finance • 10 days ago

Here Are Monday’s Top Wall Street Analyst Research Calls: Applied Materials, CoreWeave, Deckers Outdoor, F5, Lam Research, Salesforce, ServiceNow, Zscaler, and More

Quick Read: Based on the Schiller PE metric, after a week of big gains leading up to Friday’s sell-off, the market is now trading at its most expensive level since the dot-com crash. Treasury Yields hit their highest level in almost 20 ye... Full story

Yahoo Finance • 10 days ago

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda

A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint. Continue Reading... Full story

Yahoo Finance • 11 days ago

3 Reasons to Sell REGN and 1 Stock to Buy Instead

Regeneron has been treading water for the past six months, recording a small return of 3.4% while holding steady at $717.22. The stock also fell short of the S&P 500’s 9.9% gain during that period. Is there a buying opportunity in Regener... Full story

Yahoo Finance • 12 days ago

Regeneron hit with late-stage trial setback for Libtayo combo against Merck’s Keytruda

[Tumor - Cancer cells] peterschreiber.media Regeneron (REGN [https://seekingalpha.com/symbol/REGN]) has announced a failure in a late-stage trial designed to evaluate a combination therapy involving its anti-PD-1 immunotherapy Libtayo aga... Full story